Prediction: Rigetti's Revenue Passes $50 Million a Year Before 2029

Rigetti's Q2 revenue rose 185% year over year to $5.1 million and gross margin expanded 1,200bps to 43%, while its $8.4 million C-DAC quantum-system order is expected to be recognized in Q4. However, operating loss widened by $8.2 million to $28.1 million as R&D expense reached $20.7 million, underscoring that growth remains far below spending. A potential $100 million Commerce Department R&D award and $541 million of cash/investments provide funding runway, but the stock remains expensive at roughly $5.2 billion, or about 100x projected 2028 sales, after falling 74% from its 52-week high.

Analysis

RGTI’s investable issue is not whether quantum demand exists, but whether its lumpy, acceptance-based hardware revenue can support a $5B-plus enterprise value before dilution becomes relevant. A single delayed commissioning can materially miss quarterly expectations, while the cost base implies that incremental gross profit will not meaningfully narrow losses for several years. The Commerce funding reduces technology-financing risk, but milestone tranches should be valued as contingent R&D support rather than backlog; government ownership may also constrain strategic flexibility or create an overhang for future capital raises.

The strongest second-order beneficiary is HPE: quantum testbed deployments reinforce HPE’s position as the orchestration layer linking quantum accelerators to conventional HPC, without requiring HPE to assume qubit-performance risk. HPE can monetize servers, networking, storage and services regardless of whether RGTI, IonQ (IONQ), D-Wave (QBTS), or a private competitor wins the hardware layer. Conversely, RGTI’s institutional installations are likely to expand the qualified-vendor universe over time, limiting the scarcity premium currently embedded across public quantum equities.

Near term, the stock can trade sharply on installation milestones and any evidence of repeat system demand, but the asymmetric risk remains downside: the market is capitalizing a multi-year revenue ramp before recurring cloud utilization or service revenue validates the installed base. Over 6-18 months, the key falsifier for a bearish valuation thesis is multiple independent follow-on orders at improving gross margin, not one-off national-lab contracts. Watch cash burn per quarter, acceptance timing, and whether 2027 guidance begins to show recurring revenue rather than project concentration.

Contrarian view: the recent drawdown does not itself create value if the valuation still assumes a successful scale-up. However, a delayed installation or a weaker-than-expected 2027 order pipeline could reset revenue expectations faster than cash runway concerns emerge, creating a more attractive entry only after the market prices hardware execution risk.

Key Decisions for Investors

• Maintain/establish a tactical short bias in RGTI only on strength into system-delivery headlines; use a defined-risk 3-6 month put spread rather than an outright short given quantum-sector squeeze risk. Thesis target is valuation compression if acceptance or follow-on backlog disappoints; exit if management demonstrates repeat customer orders and gross margin sustainably exceeds 50%.
• Prefer HPE over RGTI for quantum-HPC exposure over the next 12-18 months: HPE captures integration spending across hardware vendors and has less dependence on any single qubit roadmap. Treat this as a relative-value expression, long HPE/short RGTI in modest dollar-neutral size, with the spread invalidated by material RGTI recurring-revenue traction or a major HPE guidance cut.
• Do not underwrite the Commerce award as revenue. Set an event alert for disclosed milestone achievement, funding receipts, government-equity terms, and revised cash-burn guidance; these determine whether the award is genuinely non-dilutive support or merely extends spending.
• Reassess RGTI after the next major installation acceptance: a confirmed delivery is tradable only if it is accompanied by 2027 backlog visibility or repeat-order evidence. A revenue beat driven solely by one acceptance event should be sold into, since it does not solve customer concentration or operating leverage.